Disruptive behavior disorders represent a continuous pattern of rebellious and hostile behavior that interferes with the daily routine of an individual and affects people within close proximity as well. Physical aggression, temper tantrums, excessive disagreement behavior and other forms of resistance against other individuals are some of the behaviors observed prominently. Conduct disorder (CD) and oppositional defiant disorder (ODD) constitute disruptive behavior disorders and their symptoms are easily noticed as they interfere with their regular behavior and social skills and these symptoms usually intensify over the time.
It has been observed that typical disruptive behavior of the patients closely resembles to that of attention deficit hyperactivity disorder (ADHD), especially with reference to impulsive and hyperactive behavior, however, these conditions are distinct and occur independently. Children are highly susceptible to these disorders and around more than one third of the children with ADHD have coexisting ODD and around one quarter of ADHD children have conduct disorder. The quality of life of the patients is hampered to a large extent as their negative behavior results in conflicts with the people they interact. Early detection and treatment for these disorders might help the patient to manage the symptoms or negative behavior.
ODD patients exhibit mutinous, disobedient and hostile behavior towards authority figures and may frequently argue with adults and may exhibit short temper, impulsive, resentful and even violent behavior. The delayed diagnosis and treatment of this condition may worsen the symptoms and may become severe eventually leading to CD. Conduct disorder is a more extreme condition as compared to ODD as the CD patients exhibit serious aggression, deliberate destruction of other’s property and steal the things from others. It has been observed that the children with CD could have been diagnosed with ODD at an earlier stage resulting in retention of ODD symptoms as well. Owing to these cluster of behavior patterns may lead to prominent illegal behavior and substance abuse. The CD or ADHD patients have a greater chance of experiencing learning disabilities such as verbal impairment and other reading disorders thereby hampering their productivity and efficiency.
ODD is diagnosed usually if the children demonstrate the above mentioned symptoms for atleast six months and also this need to be distinguished from the other disorders with similar symptoms. Treatment approaches include behavior modification therapy and sometimes drugs are administered to alleviate the symptoms. Behavior modification therapy involves imparting social skills by conducting group based improvement therapies and results in improving child’s social behavior. Furthermore, drugs are administered to treat depressive and anxiety disorders. The diagnosis of conduct disorder is based on the history of symptoms observed over a period of time. Psychotherapy may help the patients with comorbid disorders and in certain cases the patients may require considerable supervision and personal attention. It has been observed that CD is prevalent in boys than girls.
The market for disruptive behavior disorders can be analyzed by assessing the therapeutics scenario and a geographical landscape elucidating the market across the four major geographies namely North America, Asia-Pacific, Europe and Rest of the World. The pipeline analysis of the drugs against disruptive behavior disorders is based on several parameters such as route of administration, target molecules, mechanism of action and safety of the drugs. SUVN-502, SPN-812, ORADUR-ADHD and AZ-5213 are some of the drugs in investigational phases indicated for disruptive behavior disorders.
Some of the major factors favoring the market growth are consistent increase in the comorbid disorders followed by increasing investments by pharmaceutical companies to develop therapeutics against disruptive behavior disorders. On the other hand, negligence towards diagnosis of these disorders followed by lack of explicit treatment approaches might hamper the market growth. Eli Lilly and Co., Pfizer, Inc., DURECT Corporation, Johnson & Johnson, Chelsea Therapeutics, Inc., and Bionomics Ltd are some of the companies involved in developing therapeutics against disruptive behavior disorders.
This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.